MMSI on Nasdaq
MERIT MEDICAL SYSTEMS INC
MERIT MEDICAL SYSTEMS INC is a leading manufacturer and marketer of proprietary medical devices used in interventional.2 It is headquartered in South Jordan, United States.2 Its shares trade on Nasdaq under the symbol MMSI.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with INTEGRA LIFESCIENCES HOLDINGS CORP, Penumbra or Haemonetics, or pick any stock.
- TickerMMSI on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersSouth Jordan, United States2
- Incorporated inUT3
- Business address1600 West Merit Park Way, South Jordan, Ut 840953
- Filer categoryLarge accelerated filer3
- Legal formProfit Corporation2
- LEI549300OYTY138SP2CE832
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O UNITED AGENT GROUP INC., 84790 Saint George, United States2
- Registered withUtah Division of Corporations & Commercial Code (Department of Commerce), 973252-01422
See how the biggest companies compare on our leaderboards
Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. We strive to be the most customer-focused company in healthcare. Each day we are determined to make a difference by understanding our customers’ needs and innovating and delivering a diverse range of products that improve the lives of people and communities throughout the world. We believe that long-term value is created for our customers, employees, shareholders, and communities when we focus outward and are determined to deliver an exceptional customer experience.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
48.7%Gross margin6
12.2%Operating margin6
8.5%Net margin6
11.8%Revenue growth, 20256
8.1%Return on equity6
0.46×Debt to equity6
$215.7MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Cardiovascular brought in 95% of the revenue MERIT MEDICAL SYSTEMS INC broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cardiovascular | $1.2B | $1.3B | $1.4B |
| Endoscopy | $36.8M | $54.8M | $72.9M |
Regions
United States brought in 60% of the revenue MERIT MEDICAL SYSTEMS INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $727.0M | $800.8M | $909.5M |
| Outside the United States | $530.4M | $555.7M | $606.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue51¢$777.6M
- Selling, general and admin30¢$455.2M
- Other costs7¢$112.1M
- Income tax3¢$42.4M
- Profit8¢$128.5M
Out of $1.5B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending27¢$81.7M
- Kept or used elsewhere73¢$215.7M
Out of $297.4M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net sales | $1.5B | $1.4B | $1.3B |
| Cost of sales | $777.6M | $713.2M | $673.5M |
| Gross profit | $738.3M | $643.3M | $583.9M |
| Selling, general and administrative | $455.2M | $399.7M | $373.7M |
| Research and development | $97.4M | $87.5M | $82.7M |
| Impairment charges | $270.0K | ||
| Contingent consideration expense | $984.0K | $443.0K | $1.7M |
| Acquired in-process research and development | $1.6M | ||
| Total operating expenses | $553.5M | $487.6M | $459.9M |
| Income from operations | $184.7M | $155.7M | $123.9M |
| Interest income | $15.1M | $26.2M | $2.5M |
| Interest expense | -$26.5M | -$31.2M | -$15.5M |
| Other (expense) income - net | -$2.4M | -$711.0K | $1.2M |
| Total other expense - net | -$13.8M | -$5.7M | -$11.9M |
| Income before income taxes | $170.9M | $150.0M | $112.1M |
| Income tax expense | $42.4M | $29.6M | $17.7M |
| Net income | $128.5M | $120.4M | $94.4M |
| Basic (in dollars per share) | $2.17 | $2.07 | $1.64 |
| Diluted (in dollars per share) | $2.13 | $2.03 | $1.62 |
| Basic (in shares) | 59.2M shares | 58.2M shares | 57.6M shares |
| Diluted (in shares) | 60.5M shares | 59.4M shares | 58.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $446.4M | $376.7M | $587.0M | |
| Trade receivables - net of allowance for credit losses - 2025 - $10,136 and 2024 - $9,729 | $203.7M | $190.2M | ||
| Other receivables | $17.8M | $16.6M | ||
| Inventories | $333.7M | $306.1M | ||
| Prepaid expenses and other current assets | $31.5M | $28.5M | ||
| Prepaid income taxes | $4.9M | $3.3M | ||
| Income tax refund receivables | $2.1M | $2.3M | ||
| Total current assets | $1.0B | $923.8M | ||
| Land and land improvements | $30.5M | $25.8M | ||
| Buildings | $200.0M | $192.3M | ||
| Manufacturing equipment | $365.3M | $340.9M | ||
| Furniture and fixtures | $60.9M | $61.3M | ||
| Leasehold improvements | $65.2M | $58.8M | ||
| Construction-in-progress | $82.9M | $58.7M | ||
| Total property and equipment | $804.8M | $737.8M | ||
| Less accumulated depreciation | -$376.4M | -$351.6M | ||
| Property and equipment - net | $428.4M | $386.2M | $383.5M | |
| Goodwill | $506.8M | $463.5M | $382.2M | |
| Deferred income tax assets | $7.0M | $16.0M | ||
| Right-of-use operating lease assets | $87.6M | $65.5M | ||
| Other assets | $78.2M | $65.3M | ||
| Total other assets | $1.2B | $1.1B | ||
| Total assets | $2.7B | $2.4B | ||
| Trade payables | $60.6M | $68.5M | ||
| Accrued expenses | $159.5M | $134.1M | ||
| Short-term operating lease liabilities | $10.9M | $10.3M | ||
| Income taxes payable | $8.9M | $3.5M | ||
| Total current liabilities | $239.8M | $216.4M | ||
| Long-term debt | $734.0M | $729.6M | ||
| Deferred income tax liabilities | $19.7M | $240.0K | ||
| Liabilities related to unrecognized tax benefits | $2.2M | $2.1M | ||
| Deferred compensation payable | $17.5M | $19.2M | ||
| Deferred credits | $1.4M | $1.5M | ||
| Long-term operating lease liabilities | $76.7M | $54.8M | ||
| Other long-term obligations | $10.3M | $15.5M | ||
| Total liabilities | $1.1B | $1.0B | ||
| Preferred stock - 5,000 shares authorized; no shares issued as of December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, no par value - 100,000 shares authorized; issued and outstanding as of December 31, 2025 - 59,424 and December 31, 2024 - 58,743 | $763.9M | $703.2M | ||
| Retained earnings | $824.0M | $695.5M | ||
| Accumulated other comprehensive loss | -$3.6M | -$19.4M | ||
| Total stockholders' equity | $1.6B | $1.4B | $1.2B | $1.1B |
| Total liabilities and stockholders' equity | $2.7B | $2.4B | ||
| Trade receivables, allowances | $10.1M | $9.7M | ||
| Preferred stock shares authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock shares issued (in shares) | 59.4M shares | 58.7M shares | ||
| Common stock shares outstanding (in shares) | 59.4M shares | 58.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $446.4M | $376.7M | $587.0M | |
| Trade receivables - net of allowance for credit losses - 2025 - $10,136 and 2024 - $9,729 | $203.7M | $190.2M | ||
| Other receivables | $17.8M | $16.6M | ||
| Inventories | $333.7M | $306.1M | ||
| Prepaid expenses and other current assets | $31.5M | $28.5M | ||
| Prepaid income taxes | $4.9M | $3.3M | ||
| Income tax refund receivables | $2.1M | $2.3M | ||
| Total current assets | $1.0B | $923.8M | ||
| Land and land improvements | $30.5M | $25.8M | ||
| Buildings | $200.0M | $192.3M | ||
| Manufacturing equipment | $365.3M | $340.9M | ||
| Furniture and fixtures | $60.9M | $61.3M | ||
| Leasehold improvements | $65.2M | $58.8M | ||
| Construction-in-progress | $82.9M | $58.7M | ||
| Total property and equipment | $804.8M | $737.8M | ||
| Less accumulated depreciation | -$376.4M | -$351.6M | ||
| Property and equipment - net | $428.4M | $386.2M | $383.5M | |
| Goodwill | $506.8M | $463.5M | $382.2M | |
| Deferred income tax assets | $7.0M | $16.0M | ||
| Right-of-use operating lease assets | $87.6M | $65.5M | ||
| Other assets | $78.2M | $65.3M | ||
| Total other assets | $1.2B | $1.1B | ||
| Total assets | $2.7B | $2.4B | ||
| Trade payables | $60.6M | $68.5M | ||
| Accrued expenses | $159.5M | $134.1M | ||
| Short-term operating lease liabilities | $10.9M | $10.3M | ||
| Income taxes payable | $8.9M | $3.5M | ||
| Total current liabilities | $239.8M | $216.4M | ||
| Long-term debt | $734.0M | $729.6M | ||
| Deferred income tax liabilities | $19.7M | $240.0K | ||
| Liabilities related to unrecognized tax benefits | $2.2M | $2.1M | ||
| Deferred compensation payable | $17.5M | $19.2M | ||
| Deferred credits | $1.4M | $1.5M | ||
| Long-term operating lease liabilities | $76.7M | $54.8M | ||
| Other long-term obligations | $10.3M | $15.5M | ||
| Total liabilities | $1.1B | $1.0B | ||
| Preferred stock - 5,000 shares authorized; no shares issued as of December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, no par value - 100,000 shares authorized; issued and outstanding as of December 31, 2025 - 59,424 and December 31, 2024 - 58,743 | $763.9M | $703.2M | ||
| Retained earnings | $824.0M | $695.5M | ||
| Accumulated other comprehensive loss | -$3.6M | -$19.4M | ||
| Total stockholders' equity | $1.6B | $1.4B | $1.2B | $1.1B |
| Total liabilities and stockholders' equity | $2.7B | $2.4B | ||
| Trade receivables, allowances | $10.1M | $9.7M | ||
| Preferred stock shares authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock shares issued (in shares) | 59.4M shares | 58.7M shares | ||
| Common stock shares outstanding (in shares) | 59.4M shares | 58.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income (Loss) | $128.5M | $120.4M | $94.4M |
| Depreciation and amortization | $123.2M | $102.7M | $90.0M |
| Gain on disposition of business | -$249.0K | -$431.0K | |
| Loss on sale or abandonment of property and equipment | $2.3M | $1.5M | $5.8M |
| Write-off of certain intangible assets and other long-term assets | $313.0K | $456.0K | $506.0K |
| Acquired in-process research and development | $1.6M | ||
| Amortization of right-of-use operating lease assets | $11.5M | $12.0M | $11.3M |
| Fair value adjustments related to contingent consideration liabilities | $984.0K | $443.0K | $1.7M |
| Amortization of deferred credits | -$103.0K | -$103.0K | -$104.0K |
| Amortization and write-off of long-term debt issuance costs | $5.7M | $6.8M | $1.7M |
| Deferred income taxes | $5.2M | -$14.9M | -$12.6M |
| Stock-based compensation expense | $43.5M | $28.5M | $21.3M |
| Trade receivables | -$7.3M | -$13.7M | -$11.9M |
| Other receivables | $4.4M | -$6.5M | $2.4M |
| Inventories | -$21.6M | -$2.3M | -$32.1M |
| Prepaid expenses and other current assets | -$2.5M | -$4.3M | $1.3M |
| Prepaid income taxes | -$1.6M | $709.0K | -$92.0K |
| Income tax refund receivables | $246.0K | -$1.5M | -$58.0K |
| Other assets | -$1.7M | -$6.1M | -$6.0M |
| Trade payables | $1.0M | -$2.3M | -$7.3M |
| Accrued expenses | $14.3M | $9.7M | -$2.5M |
| Income taxes payable | $5.2M | -$1.8M | -$1.7M |
| Liabilities related to unrecognized tax benefits | $80.0K | $206.0K | |
| Deferred compensation payable | -$1.7M | $2.0M | $1.9M |
| Operating lease liabilities | -$11.2M | -$12.2M | -$11.5M |
| Other long-term obligations | -$947.0K | $1.0M | -$2.5M |
| Total adjustments | $168.9M | $100.4M | $50.7M |
| Net cash, cash equivalents, and restricted cash provided by operating activities | $297.4M | $220.8M | $145.2M |
| Property and equipment | -$81.7M | -$35.1M | -$34.3M |
| Intangible assets | -$3.1M | -$2.9M | -$2.4M |
| Proceeds from asset and business dispositions | $303.0K | $5.0K | $632.0K |
| Cash paid for notes receivable and other investments | -$18.1M | -$10.4M | -$4.8M |
| Cash paid in acquisitions, net of cash acquired | -$144.8M | -$320.2M | -$134.5M |
| Net cash, cash equivalents, and restricted cash used in investing activities | -$247.4M | -$368.7M | -$175.3M |
| Proceeds from issuance of common stock | $28.2M | $40.9M | $15.6M |
| Proceeds from issuance of long-term debt | $1.2B | ||
| Payments on long-term debt | -$99.1M | -$579.6M | |
| Purchase of capped call option | -$66.5M | ||
| Long-term debt issuance costs | -$677.0K | ||
| Contingent payments related to acquisitions | -$2.7M | -$261.0K | -$3.6M |
| Payment of taxes related to an exchange of common stock | -$9.5M | -$1.6M | -$5.1M |
| Net cash, cash equivalents, and restricted cash provided by (used in) financing activities | $16.0M | -$60.0M | $559.3M |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | $3.8M | -$2.5M | -$484.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $69.8M | -$210.4M | $528.6M |
| Interest (net of capitalized interest of $1,398, $1,005 and $1,272, respectively) | $21.0M | $23.2M | $14.1M |
| Income taxes | $31.4M | $45.0M | $31.5M |
| Property and equipment purchases in accounts payable | $3.1M | $13.2M | $8.3M |
| Acquisition purchases in accrued expenses and other long-term obligations | $3.9M | $5.0M | $3.7M |
| Merit common stock surrendered (118, 0 and 86 shares, respectively) in exchange for exercise of stock options | $10.9M | $5.8M | |
| Right-of-use operating lease assets obtained in exchange for operating lease liabilities | $32.7M | $9.9M | $8.9M |
| Net capitalized interest | $1.4M | $1.0M | $1.3M |
| Common stock surrendered in exchange for exercise of stock options (in shares) | 118.0K shares | 0 shares | 86.0K shares |
No quarter-by-quarter statement was filed.
Corporate structure
MERIT MEDICAL SYSTEMS INC sits at the top of its group. 53 entities, 36 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of MERIT MEDICAL SYSTEMS INC
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on MERIT MEDICAL SYSTEMS INC, latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on MERIT MEDICAL SYSTEMS INC, latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on MERIT MEDICAL SYSTEMS INC, latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on MERIT MEDICAL SYSTEMS INC, latest Oct 17, 2025 (8 filings since Jan 25, 2022)
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Filed SC 13G/A on MERIT MEDICAL SYSTEMS INC, latest Nov 14, 2024 (4 filings since Feb 10, 2022)
- ArrowMark Colorado Holdings LLC Filed SC 13G/A on MERIT MEDICAL SYSTEMS INC, latest Feb 15, 2023 (2 filings since Feb 14, 2022)
- Starboard Value LP Filed SC 13D/A on MERIT MEDICAL SYSTEMS INC, latest Oct 18, 2021
- MERIT MEDICAL SYSTEMS INC South Jordan, Utah, United States
- Biolife Delaware, LLC Subsidiary · Delaware, United States
- Biolife Management Services, LLC Subsidiary · Florida, United States
- BioSphere Medical Japan, Inc. Subsidiary · Delaware, United States
- BioSphere Medical SA Subsidiary · France
- Brightwater Medical, Inc. Subsidiary · Delaware, United States
- Cianna Medical, Inc. Subsidiary · Delaware, United States
- Dfine Europe GmbH Subsidiary · Germany
- DFINE, Inc. Subsidiary · Delaware, United States
- KA Medical, LLC Subsidiary · Minnesota, United States
- LLC Merit Technologies Subsidiary · Russia
- Merit Holdings, Inc. Subsidiary · Utah, United States
- Merit Maquiladora México, S. de R.L. de C.V. Subsidiary · Mexico
- Merit Medical (Thailand) Limited Subsidiary · Thailand
- Merit Medical Africa (Pty) LTD Subsidiary · South Africa
- Merit Medical Asia Company Limited Subsidiary · Hong Kong
- Merit Medical Australia Pty Ltd. Subsidiary · Australia
- Merit Medical Austria GmbH Subsidiary · Austria
- Merit Medical Beijing Co. Ltd. Subsidiary · China
- Merit Medical Belgium Sprl (BVBA) Subsidiary · Belgium
- Merit Medical Canada Ltd. Subsidiary · Canada
- Merit Medical Coatings B.V. Subsidiary · Netherlands
- Merit Medical Colombia S.A.S. Subsidiary · Colombia
- Merit Medical Comercialização, Distribuição, Importação e Exportação de Produtos Hospitalares LTDA. Subsidiary · Brazil
- Merit Medical Denmark A/S Subsidiary · Denmark
- Merit Medical Egypt LLC Subsidiary · Egypt
- and 27 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What MERIT MEDICAL SYSTEMS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Land | $30.5M6 Dec 31, 2025 | $25.8M6 Dec 31, 2024 | +17.9% |
| Buildings and improvements | $200.0M6 Dec 31, 2025 | $192.3M6 Dec 31, 2024 | +4.0% |
| Machinery and equipment | $365.3M6 Dec 31, 2025 | $340.9M6 Dec 31, 2024 | +7.2% |
| Furniture and fixtures | $60.9M6 Dec 31, 2025 | $61.3M6 Dec 31, 2024 | −0.7% |
| Leasehold improvements | $65.2M6 Dec 31, 2025 | $58.8M6 Dec 31, 2024 | +11.0% |
| Construction in progress | $82.9M6 Dec 31, 2025 | $58.7M6 Dec 31, 2024 | +41.4% |
| Property and equipment, before depreciation | $804.8M6 Dec 31, 2025 | $737.8M6 Dec 31, 2024 | +9.1% |
| Accumulated depreciation | $376.4M6 Dec 31, 2025 | $351.6M6 Dec 31, 2024 | +7.1% |
| Property and equipment, net | $428.4M6 Dec 31, 2025 | $386.2M6 Dec 31, 2024 | +10.9% |
| Operating-lease assets (leased space) | $87.6M6 Dec 31, 2025 | $65.5M6 Dec 31, 2024 | +33.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $446.4M6 Dec 31, 2025 | $376.7M6 Dec 31, 2024 | +18.5% |
Intangibles and goodwill
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $333.7M6 Dec 31, 2025 | $306.1M6 Dec 31, 2024 | +9.0% |
| Raw materials | $110.7M6 Dec 31, 2025 | $110.5M6 Dec 31, 2024 | +0.2% |
| Work in process | $32.4M6 Dec 31, 2025 | $27.1M6 Dec 31, 2024 | +19.5% |
| Finished goods | $190.6M6 Dec 31, 2025 | $168.4M6 Dec 31, 2024 | +13.2% |
Properties, in its own words
Our world headquarters is located in South Jordan, Utah, with our principal office for European operations located in Galway, Ireland and our principal office for Asian distribution located in Beijing, China. We also support our European operations from a distribution and customer service facility located in Maastricht, The Netherlands. In addition, we lease commercial space in India, Hong Kong, Italy, Dubai, Australia, Canada, Brazil, Malaysia, South Korea, Japan, South Africa, Singapore, Great Britain, Vietnam, Taiwan, New Zealand, Indonesia, and France, as well as in California and Texas. Our principal manufacturing and packaging facilities are located in Utah, Virginia, Texas, Florida, Ireland, Brazil, Singapore, Mexico, France and The Netherlands. Our research and development activities are conducted principally at facilities located in Utah, California, Texas, Ireland and France.
Our total manufacturing, commercial, distribution, and research space is approximately 2.2 million square feet, of which approximately 1.2 million square feet is owned, and 1.0 million square feet is leased.
The rest of Item 2
The following is a summary of the approximate square footage of our key facilities:
Location · Main Purpose · Area (sq. ft.)
Utah · HQ, Manufacturing, Distribution, Research · 932,735
Mexico · Manufacturing · 262,020
Virginia · Manufacturing, Distribution · 187,659
The Netherlands · Manufacturing, Distribution · 162,646
Ireland · Manufacturing, Research · 139,680
Texas · Manufacturing, Research · 98,995
Singapore · Manufacturing · 68,000
China · Distribution · 58,521
Operations associated with our cardiovascular segment utilize all of our facilities, while operations associated with our endoscopy segment are conducted primarily from our facilities located in Utah and Texas.
We believe our existing and proposed facilities will generally be adequate for our present and future anticipated levels of operations.
Item 2 of the 10-K filed Feb 24, 2026.5
Leadership
Who has led MERIT MEDICAL SYSTEMS INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerMartha Goldberg Aronson Oct 7, 2025 to now14
- Chief executive officerFred P. Lampropoulos Jan 20, 2006 to Oct 7, 202515
- ChairFred P. Lampropoulos Nov 20, 2025 to now16
- PresidentMartha Goldberg Aronson Oct 7, 2025 to now14
- PresidentJustin J. Lampropoulos Mar 2, 2021 to Mar 23, 202117
- PresidentFred P. Lampropoulos Jan 20, 2006 to Mar 2, 202115
- Chief financial officerRaul Parra Jr. Jun 7, 2018 to now18
- Chief financial officerBernard Birkett Nov 16, 2015 to Mar 6, 201819
- Chief financial officerKent W. Stanger Jan 20, 2006 to Mar 3, 201620
- Chief operating officerRonald Frost Jan 9, 2014 to Aug 12, 202221
- Chief operating officerB. Leigh Weintraub Jan 20, 2006 to Nov 30, 200622
- Chief operating officerArlin D. Nelson Dec 12, 2006 to Aug 2, 201323
Board members and other officers (29)
- EVP of Global OperationsSheri Lewis Sep 1, 2026 to now24
- Chief Strategy & Innovation O.Robert Fredericks Jun 2, 2022 to Jun 2, 202225
- Chief Human Resources OfficerMichel James Voigt Dec 21, 2020 to now26
- EXEC. V.P. MKTG & STRATEGYJustin J. Lampropoulos Jun 1, 2015 to Feb 28, 202027
- Chief Accounting OfficerGreg L. Barnett Jan 20, 2006 to Aug 3, 201528
- VP of SalesMartin R. Stephens Jan 20, 2006 to Feb 18, 201529
- Board memberScott R. Ward May 19, 2026 to now30
- Board memberMartha Goldberg Aronson Oct 7, 2025 to now14
- Board memberSilvia Perez May 20, 2024 to now31
- Board memberLaura S. Kaiser May 26, 2022 to now32
- Board memberMichael R. McDonnell May 26, 2022 to now33
- Board memberStephen C. Evans Jun 21, 2021 to now34
- Board memberJames T. Hogan Jun 24, 2020 to May 26, 202235
- Board memberLonny J. Carpenter Jun 24, 2020 to now36
- Board memberElizabeth Huebner Jan 10, 2019 to Jan 10, 201937
- Board memberJill Anderson Jan 10, 2019 to Sep 13, 202138
- Board memberLynne Ward Aug 22, 2019 to now39
- Board memberThomas James Gunderson Jun 1, 2017 to now40
- Board memberF. Ann Millner Jul 27, 2015 to now41
- Board memberA. Scott Anderson Nov 15, 2011 to Aug 14, 202342
- Board memberNolan E. Karras Nov 15, 2011 to May 29, 202043
- Board memberFred P. Lampropoulos Jan 20, 2006 to now15
- Board memberKent W. Stanger Jan 20, 2006 to Jan 23, 202020
- Board memberJames J. Ellis Feb 14, 2006 to Aug 15, 201144
- Board memberRex C. Bean Feb 14, 2006 to Jun 6, 201345
- Board memberMichael E. Stillabower Jun 21, 2006 to Aug 6, 201946
- Board memberRichard W. Edelman Jun 21, 2006 to May 26, 201747
- Board memberFranklin J. Miller Jun 30, 2006 to Mar 13, 202048
- General counselRashelle Perry Jan 20, 2006 to Dec 2, 201549
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- BioSphere Medical Japan, Inc. Delaware4
- BioSphere Medical SA France4
- BioSphere Medical, Inc. Delaware4
- Biolife Delaware, LLC Delaware4
- Biolife Management Services, LLC Florida4
- Brightwater Medical, Inc. Delaware4
- Cianna Medical, Inc. Delaware4
- DFINE, Inc. Delaware4
- Dfine Europe GmbH Germany4
- KA Medical, LLC Minnesota4
- LLC Merit Technologies Russia4
- Merit Holdings, Inc. Utah4
- Merit Maquiladora México, S. de R.L. de C.V. Mexico4
- Merit Medical (Thailand) Limited Thailand4
- Merit Medical Africa (Pty) LTD South Africa4
- Merit Medical Asia Company Limited Hong Kong4
- Merit Medical Australia Pty Ltd. Australia4
- Merit Medical Austria GmbH Austria4
- Merit Medical Beijing Co. Ltd. China4
- Merit Medical Belgium Sprl (BVBA) Belgium4
- Merit Medical Canada Ltd. Canada4
- Merit Medical Coatings B.V. Netherlands4
- Merit Medical Colombia S.A.S. Colombia4
- Merit Medical Comercialização, Distribuição, Importação e Exportação de Produtos Hospitalares LTDA. Brazil4
All 54 listed subsidiaries
- Merit Medical Denmark A/S Denmark4
- Merit Medical Egypt LLC Egypt4
- Merit Medical Finland Ltd. Finland4
- Merit Medical France SAS France4
- Merit Medical GmbH Germany4
- Merit Medical Ireland, Ltd. Ireland4
- Merit Medical Italy S.R.L. Italy4
- Merit Medical Japan KK Japan4
- Merit Medical Korea Co., Ltd. South Korea4
- Merit Medical ME FZ-LLC United Arab Emirates4
- Merit Medical Malaysia Sdn. Bhd Malaysia4
- Merit Medical Nederland B.V. Netherlands4
- Merit Medical New Zealand Limited New Zealand4
- Merit Medical Norway AS Norway4
- Merit Medical Poland sp.z.o.o. Poland4
- Merit Medical Portugal, S.A. Portugal4
- Merit Medical Singapore Pte. Ltd. Singapore4
- Merit Medical South Africa (Pty) LTD South Africa4
- Merit Medical Spain S.L. Spain4
- Merit Medical Switzerland AG Switzerland4
- Merit Medical Systems AB Sweden4
- Merit Medical Systems India Private Limited India4
- Merit Medical Turkey Tıbbi Ürünler Ticaret Anonim Şirketi Turkey4
- Merit Medical UK Limited United Kingdom4
- Merit Mexico Sales, S. de R.L. de C.V. Mexico4
- Merit Sensor Systems, Inc. Utah4
- PT Merit Medical Systems Indonesia Indonesia4
- Restore Endosystems, LLC Delaware4
- Thomas Medical Products, Inc. Pennsylvania4
- Vascular Access Technologies, Inc. Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 20, 20268-K Executive or director change; Regulation FD disclosure50
- Jul 30, 20268-K Results of operations; Regulation FD disclosure51
- May 19, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote52
- Apr 30, 20268-K Results of operations; Regulation FD disclosure53
- Apr 13, 20268-K Regulation FD disclosure54
- Apr 1, 20268-K Regulation FD disclosure55
- Feb 24, 20268-K Results of operations; Regulation FD disclosure56
- Jan 8, 20268-K Results of operations; Executive or director change; Regulation FD disclosure57
- Nov 13, 20258-K Regulation FD disclosure58
- Nov 3, 20258-K Regulation FD disclosure59
- Oct 30, 20258-K Results of operations; Regulation FD disclosure60
- Oct 17, 20258-K Regulation FD disclosure61
- Oct 7, 2025New chief executive Martha Goldberg Aronson becomes CEO14
- Jan 20, 2006New chief executive Fred P. Lampropoulos becomes CEO15
- Jul 28, 1987Founded MERIT MEDICAL SYSTEMS INC is founded2
Calendar
Coming up
- Oct 29, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.79 a share, on Oct 30, 2025.62
When it reported results
- Jul 30, 2026Reported quarterly or annual results51
- Apr 30, 2026Reported quarterly or annual results53
- Feb 24, 2026Reported quarterly or annual results56
- Jan 8, 2026Reported quarterly or annual results57
- Oct 30, 2025Reported quarterly or annual results60
- Jul 30, 2025Reported quarterly or annual results63
- Jul 11, 2025Reported quarterly or annual results64
- May 20, 2025Reported quarterly or annual results65
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
351 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 54 major events, 165 insider forms, 21 large holders, 90 other. The latest 20:
- Sep 9, 20264 EDGAR
- Sep 1, 20263 EDGAR
- Aug 25, 20264 EDGAR
- Aug 25, 20264 EDGAR
- Aug 24, 2026144 EDGAR
- Aug 20, 20268-K EDGAR
- Aug 5, 20264 EDGAR
- Aug 4, 2026144 EDGAR
- Jul 30, 202610-Q EDGAR
- Jul 30, 20268-K EDGAR
- Jun 29, 2026S-8 EDGAR
- Jun 26, 202611-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 8, 20264 EDGAR
- May 29, 2026SD EDGAR
- May 21, 20264 EDGAR
- May 19, 20264 EDGAR
- May 19, 20264 EDGAR
- May 19, 20264 EDGAR
- May 19, 20264 EDGAR
The 351 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
62 open-market trades by officers, directors and large owners since October 2021: 5 buys and 57 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Peterson Neil W.CHIEF OPERATING OFFICER | Sale | 7,500 | $90.45 | $678.4K | Form 4 |
| Aug 4, 2026 | Peterson Neil W.CHIEF OPERATING OFFICER | Sale | 21,449 | $85.00 | $1.8M | Form 4 |
| May 11, 2026 | Smith Christian AdamChief Commercial Officer | Buy | 1,626 | $61.00 | $99.2K | Form 4 |
| May 7, 2026 | Ward Lynne N.Director | Sale | 5,000 | $62.61 | $313.1K | Form 4 |
| May 7, 2026 | Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY | Buy | 2,000 | $62.63 | $125.3K | Form 4 |
| May 6, 2026 | Parra Raul Jr.CFO AND TREASURER | Buy | 1,500 | $61.01 | $91.5K | Form 4 |
| May 6, 2026 | Aronson Martha GoldbergPresident and CEO | Buy | 2,000 | $60.44 | $120.9K | Form 4 |
| May 5, 2026 | Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER | Buy | 2,250 | $60.65 | $136.5K | Form 4 |
| Jan 6, 2026 | Peterson Neil W.CHIEF OPERATING OFFICER | Sale | 5,000 | $90.00 | $450.0K | Form 4 |
| Nov 25, 2025 | Lampropoulos Fred P.Director | Sale | 10,000 | $88.04 | $880.4K | Form 4 |
| Nov 21, 2025 | Lampropoulos Fred P.Director | Sale | 25,000 | $87.31 | $2.2M | Form 4 |
| Nov 20, 2025 | Lampropoulos Fred P.Director | Sale | 20,000 | $85.13 | $1.7M | Form 4 |
| Nov 18, 2025 | Lampropoulos Fred P.Director | Sale | 5,000 | $84.83 | $424.1K | Form 4 |
| Aug 22, 2025 | Ward Lynne N.Director | Sale | 3,000 | $88.56 | $265.7K | Form 4 |
| Aug 11, 2025 | Ward Lynne N.Director | Sale | 2,433 | $84.89 | $206.5K | Form 4 |
| Jun 13, 2025 | Parra Raul Jr.CFO AND TREASURER | Sale | 15,181 | $93.75 | $1.4M | Form 4 |
| Jun 10, 2025 | Lampropoulos Fred P.Director | Sale | 400 | $95.61 | $38.2K | Form 4 |
| Jun 5, 2025 | Lampropoulos Fred P.Director | Sale | 10,000 | $95.19 | $951.9K | Form 4 |
| Jun 2, 2025 | McDonnell Michael R.Director | Sale | 1,750 | $94.51 | $165.4K | Form 4 |
| May 30, 2025 | McDonnell Michael R.Director | Sale | 1,750 | $94.30 | $165.0K | Form 4 |
All 62 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202666
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202667
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202668
- BlackRockSCHEDULE 13G/A, 8 filings Jan 25, 2022 to Oct 17, 202569
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCSC 13G/A, 4 filings Feb 10, 2022 to Nov 14, 202470
- ArrowMark Colorado Holdings LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 15, 202371
- Starboard Value LPSC 13D/A, 1 filing Oct 18, 202172
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Fred P. Lampropoulos | $1.9M | $13.8M73 | |
| 2025 | Martha G. Aronson | $251.4K | $6.7M73 | |
| 2025 | Raul Parra | $630.0K | $4.8M73 | |
| 2025 | Brian G. Lloyd | $630.0K | $4.4M73 | |
| 2025 | Neil W. Peterson | $630.0K | $4.1M73 | |
| 2025 | Michel J. Voigt | $449.2K | $3.3M73 | |
| 2024 | Former Chair of the BoardCEO and President | $1.9M | $10.4M73 | |
| 2024 | Chief Financial Officer and Treasurer | $630.0K | $3.2M73 | |
| 2024 | Chief Operating Officer | $630.0K | $3.1M73 | |
| 2024 | Chief Legal OfficerCorporate Secretary | $630.0K | $3.1M73 | |
| 2023 | Former Chair of the BoardCEO and President | $1.9M | $10.1M73 | |
| 2023 | Chief Financial Officer and Treasurer | $629.4K | $2.8M73 | |
| 2023 | Chief Operating Officer | $629.4K | $2.7M73 | |
| 2023 | Chief Legal OfficerCorporate Secretary | $629.4K | $2.7M73 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 9,464,542 | $656.3M | 0.0% | +630,227 |
| Vanguard Portfolio Management LLC | 3,473,833 | $240.9M | 0.0% | −49,255 |
| Vanguard Capital Management LLC | 2,590,454 | $179.6M | 0.0% | −65,709 |
| State Street Corp | 2,474,512 | $171.6M | 0.0% | +113,530 |
| Conestoga Capital Advisors, LLC | 1,979,790 | $137.3M | 3.0% | −187,723 |
| Geode Capital Management, LLC | 1,625,950 | $112.8M | 0.0% | +117,576 |
| Fuller & Thaler Asset Management, Inc. | 1,613,002 | $111.8M | 0.3% | −502,524 |
| Dimensional Fund Advisors LP | 1,458,823 | $101.2M | 0.0% | +221,525 |
| Nomura Asset Management International Inc. | 1,279,152 | $88.7M | 0.1% | +80,883 |
| Congress Asset Management Co | 1,184,337 | $82.1M | 0.5% | +155,088 |
| William Blair Investment Management, LLC | 1,137,790 | $78.9M | 0.2% | +360,296 |
| Greenhouse Funds LLLP | 1,072,098 | $74.3M | 3.9% | −50,349 |
| Citigroup Inc | 1,022,497 | $70.9M | 0.0% | −40,218 |
| Fmr LLC | 1,012,810 | $70.2M | 0.0% | +7,872 |
| Westwood Holdings Group Inc | 1,011,377 | $70.1M | 0.5% | +64,901 |
| Morgan Stanley | 1,006,891 | $69.8M | 0.0% | −254,068 |
| Neuberger Berman Group LLC | 1,002,168 | $69.5M | 0.0% | +996,617 |
| Maverick Capital Ltd | 978,617 | $67.9M | 0.6% | +264,536 |
| Citadel Advisors LLC | 909,863 | $63.1M | 0.0% | −52,921 |
| Royal Bank Of Canada | 826,944 | $57.3M | 0.0% | −94,386 |
| Charles Schwab Investment Management Inc | 743,937 | $51.6M | 0.0% | +68,488 |
| Norges Bank | 711,160 | $49.3M | 0.0% | New |
| Northern Trust Corp | 709,267 | $49.2M | 0.0% | +27,419 |
| Massachusetts Financial Services Co /ma/ | 679,195 | $47.1M | 0.0% | +231,744 |
| Jpmorgan Chase & Co | 644,037 | $45.3M | 0.0% | +26,989 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Sep 25, 2025 | Lisa C. McClainRepublican, House | Sale | $1,001 - $15,000 | +5.4% | Report |
| Jul 22, 2025 | Lisa C. McClainRepublican, House | Buy | $1,001 - $15,000 | −16.7% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How MERIT MEDICAL SYSTEMS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARMERIT MEDICAL SYSTEMS INC1
- CIK0000856982
- Employer ID (EIN)87-04476955
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inUtah5
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address1600 West Merit Park Way, South Jordan, UT 840951
- Mailing address1600 West Merit Parkway, South Jordan, UT 840951
- Phone80125316001
- Shares outstanding59,710,420 as of Jul 28, 202612
- Public float$5.4B as of Jun 30, 20255
- AuditorDELOITTE & TOUCHE LLP, Salt Lake City, Utah PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceMay 14, 19961
- Filings1,663 in all: 4 (793), 8-K (225), 10-Q (92), SC 13G/A (76), 4/A (52), 144 (44), 5 (37), SC 13G (37)1
All 44 form types
3 (32), 10-K (30), DEF 14A (30), DEFA14A (25), 11-K (23), 8-K/A (21), UPLOAD (20), S-8 (16), ARS (13), CORRESP (13), SD (13), SC 13D/A (9), SE (7), 424B5 (6), SC 13D (6), 5/A (4), PRE 14A (4), S-3/A (4), 10-K/A (3), 10-Q/A (3), 3/A (3), CT ORDER (3), S-3 (3), EFFECT (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 11-K/A (1), 8-A12G (1), ARS/A (1), DEFR14A (1), DFAN14A (1), FWP (1), PRER14A (1), REGDEX (1), S-3ASR (1), SD/A (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Jul 30, 2026
Proxy statement (DEF 14A) Mar 31, 2026
Latest 8-K (8-K) Aug 20, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, no par value | MMSI | NASDAQ |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks MERIT MEDICAL SYSTEMS INC names in Item 1A of its 10-K filed Feb 24, 2026: 39 risks under these headings, as written.5
- Business, Economic, Industry and Operational Risks
- Disruptions in the supply from third-party vendors of the materials and components used in manufacturing or sterilizing our products could adversely affect our business, operations or financial condition.
- Cost volatility could adversely affect our operations.
- Changes in economic and geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business, operations or financial condition.
- Volatile geopolitical turmoil, including popular uprisings, regional conflicts, terrorism and war could result in market instability, which could negatively impact our financial results.
- Any damage or interruption to our operations, facilities, manufacturing processes or information technology systems, or those of our suppliers, could have an adverse effect on our business, operations or financial condition.
- Consolidation in the healthcare industry, group purchasing organizations and public cost-containment measures have led to demands for price concessions with respect to our products, which may reduce our revenues and harm our ability to sell our products at prices necessary to support our current business strategies.
- We may be unable to compete in our markets, particularly if there is a significant change in practices or technology.
- The development, deployment and use of AI in our business operations could result in regulatory action, legal liability, operational challenges or reputational harm and our failure to adapt to developments related to AI in a timely manner (or at all) could adversely affect our business, financial condition or results of operations.
- Strategic, Business Development and Employee Attraction and Retention Risks
- We may incur substantial costs when evaluating, negotiating and closing acquisitions, and our failure to integrate acquired businesses may adversely impact our business and financial results.
- Failure to realize the benefits expected from recent acquisitions could adversely affect our business, operating results or financial condition.
The other 29 risks
- If we fail to achieve projected benefits from business acquisitions or strategic investments or identify underperforming products, we may dispose of the acquired or underperforming assets, which could adversely affect our results of operations.
- Our future growth is dependent in part upon the development of new products and the enhancement of existing products, and there can be no assurance that such products be developed or enhanced.
- We may be unable to accurately forecast customer demand for our products and manage our inventory.
- Our reliance on third-party distributors could negatively impact the commercialization of our products.
- If we are unable to effectively execute our leadership succession plans and attract, develop and retain key employees, our business or results of operations could be harmed.
- Regulatory, Litigation, Tax and Legal Compliance Risks
- The FDA regulatory clearance process is extensive and dynamic, and the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing our products.
- Our products are subject to regulation in foreign countries in which we sell them. We have expended significant resources and experienced delays in obtaining foreign approvals and clearances and we will likely continue to incur significant expense, and experience delays, as we seek to obtain further approvals or clearances.
- Unsuccessful pre- and post-market clinical trials relating to our products could have a material adverse effect on our prospects.
- The medical device industry is subject to extensive scrutiny and regulation by governmental and other authorities. If governmental authorities determine that we have violated laws or regulations, our company or our employees may be subject to various penalties, including civil or criminal penalties.
- We are subject to laws targeting fraud and abuse in the healthcare industry, the violation of which could adversely affect our business, operations or financial condition.
- We are subject to the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws in non-U.S. jurisdictions, and our failure, or the failure of our distributors or agents, to comply with these laws could subject us to civil and criminal penalties and adversely affect our business, operations or financial condition.
- Limits on reimbursement imposed by governmental and other programs may adversely affect our business and results of operation.
- Use of our products in unapproved circumstances could expose us to liabilities.
- Our products may be subject to product liability claims and warranty claims.
- Our employees, independent contractors, consultants, manufacturers and distributors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- We are routinely a party to litigation, which could affect our financial condition and results of operations.
- We are subject to changes in tax laws, fluctuations in tax rates, the adoption of new tax legislation or exposure to additional tax liabilities, which may adversely affect our effective tax rate, business, financial condition, or results of operations.
- Environmental, Health and Safety and Corporate Social Responsibility Risks
- Our failure to comply with applicable environmental, health and safety laws and regulations could negatively affect our business, operations or financial condition.
- We could be negatively impacted by corporate social responsibility laws, regulations, practices and expectations.
- Our business and operations are subject to risks related to climate change.
- Intellectual Property
- We may not be able to protect our intellectual property, which could harm our business and financial condition.
- Third parties claiming that we infringe their intellectual property rights could cause us to incur significant legal or licensing expenses and prevent us from selling our products.
- Information Technology and Cybersecurity Risks
- We rely on the proper function, availability and security of information technology systems to operate our business, and a material disruption of critical information systems or a material breach in the security of our systems may adversely affect our business, reputation or financial condition.
- Market, Liquidity and Credit Risks
- The agreements and instruments governing our debt contain restrictions and limitations that could significantly affect our ability to operate our business, as well as significantly affect our liquidity.
- Our management has broad discretion regarding the use of proceeds of the Convertible Notes and other borrowed funds.
- We may not be able to service all of our indebtedness.
- The fundamental change repurchase feature of the Convertible Notes may delay or prevent an otherwise beneficial attempt to acquire us.
- The market price of our common stock has been and may continue to be volatile.
- Fluctuations in foreign currency exchange rates may negatively impact our financial results.
Legal proceedings
See Note 10 Commitments and Contingencies to our consolidated financial statements set forth in Item 8 of this report and incorporated herein by reference.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARFred P. Lampropoulos, Chair
- 17SEC EDGARJustin J. Lampropoulos, President
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARMartin R. Stephens, VP of Sales
- 30SEC EDGARScott R. Ward, Board member
- 31SEC EDGARSilvia Perez, Board member
- 32SEC EDGARLaura S. Kaiser, Board member
- 33SEC EDGARMichael R. McDonnell, Board member
- 34SEC EDGARStephen C. Evans, Board member
- 35SEC EDGARJames T. Hogan, Board member
- 36SEC EDGARLonny J. Carpenter, Board member
- 37SEC EDGARElizabeth Huebner, Board member
- 38SEC EDGARJill Anderson, Board member
- 39SEC EDGARLynne Ward, Board member
- 40SEC EDGARThomas James Gunderson, Board member
- 41SEC EDGARF. Ann Millner, Board member
- 42SEC EDGARA. Scott Anderson, Board member
- 43SEC EDGARNolan E. Karras, Board member
- 44SEC EDGARJames J. Ellis, Board member
- 45SEC EDGARRex C. Bean, Board member
- 46SEC EDGARMichael E. Stillabower, Board member
- 47SEC EDGARRichard W. Edelman, Board member
- 48SEC EDGARFranklin J. Miller, Board member
- 49SEC EDGARRashelle Perry, General counsel
- 50
- 51
- 52
- 53
- 54SEC EDGARRegulation FD disclosure
- 55SEC EDGARRegulation FD disclosure
- 56
- 57
- 58SEC EDGARRegulation FD disclosure
- 59SEC EDGARRegulation FD disclosure
- 60
- 61SEC EDGARRegulation FD disclosure
- 62NasdaqNasdaq calendar
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73